Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.

Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.

Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.